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Mutations in sarcomeric proteins have recently been established as heritable causes of Restrictive Cardiomyopathy (RCM). RCM is
clinically characterized as a defect in cardiac diastolic function, such as, impaired ventricular relaxation, reduced diastolic volume
and increased end-diastolic pressure. To date, mutations have been identiﬁed in the cardiac genes for desmin, α-actin, troponin
I and troponin T. Functional studies in skinned muscle ﬁbers reconstituted with troponin mutants have established phenotypes
consistent with the clinical ﬁndings which include an increase in myoﬁlament Ca
2+ sensitivity and basal force. Moreover, when
RCM mutants are incorporated into reconstituted myoﬁlaments, the ability to inhibit the ATPase activity is reduced. A majority
of the mutations cluster in speciﬁc regions of cardiac troponin and appear to be mutational “hot spots”. This paper highlights the
functional and clinical characteristics of RCM linked mutations within the troponin complex.
1.Introduction
Cardiac contractility is governed by the thin ﬁlament reg-
ulatory proteins, cardiac troponin (cTn) and tropomyosin
(Tm), and available levels of intracellular free calcium
([Ca2+]i). Cardiac troponin is located at regular intervals
alongthethinﬁlamentandconsistsofthreesubunits:cardiac
troponin C (cTnC), troponin I (cTnI), and troponin T
(cTnT). The cTn complex plays an important role in the
regulation of striated muscle contraction. Within the cTn
complex, cTnC acts as a Ca2+ sensor which confers Ca2+
sensitivity to muscle contraction [1]. Cardiac TnI is the
inhibitory subunit, primarily functioning to prevent actin
and myosin from interacting in the absence of Ca2+.T h e
cTnT subunit binds to tropomyosin (Tm) and is responsible
for transmitting the Ca2+ binding signal from cTn to Tm.
During systole, the rise in [Ca2+]i allows binding of Ca2+ to
the regulatory site of cTnC which leads to the movement of
Tm over the actin ﬁlament. This permits myosin to interact
with actin, subsequently leading to the generation of muscle
tension [2]. Alternatively in diastole, the [Ca2+]i levels
decline and Ca2+ dissociates from cTnC, allowing Mg2+ to
bind to the C-terminal sites. This enables the muscle to relax
and allows ventricular ﬁlling to occur. Currently, only cTnI
and cTnT have been linked to restrictive cardiomyopathy
(RCM) since no mutations have been identiﬁed in cTnC
yet. Notably, mutations in sarcomeric proteins have the
potentialtodisruptessentialthinﬁlamentinteractionswhich
can lead to the enhanced Ca2+ sensitivity of contraction,
arrhythmogenesis, cardiomyopathy and even sudden cardiac
death (SCD) [3]. This paper will address the clinical aspects,
as well as the functional studies reported to date for the
known troponin mutations associated with RCM.
2. Troponin andCardiacMuscleRegulation
The functional roles of the individual cTn subunits are
distinct and involve complex short and long range protein-
protein interactions. The binding of Ca2+ to the regulatory
site of cTnC evokes the minimal exposure of a hydrophobic
cleft within the N-domain of cTnC. This enables the
regulatory region of cTnI (residues 148–163) to associate
with cTnC [4, 5]. Structural analysis has determined that
cTnI interacts with cTnC in an antiparallel manner [5,
6]. The association of cTnI with cTnC in the presence
of Ca2+ facilitates the release of cTnI’s inhibitory region
(residues 128–147) from actin [7]. When cTnI dissociates
from actin, Tm changes its conformation and allows for2 Journal of Biomedicine and Biotechnology
the full interaction of myosin heads with actin [1]. Current
models propose that thin ﬁlament activation is regulated
by Ca2+ binding to cTnC which inﬂuences the number of
accessible cross-bridges by shifting the equilibrium from
weakly (nonforce-producing) to strongly (force-producing)
bound cross-bridges [8, 9].
Cardiac TnI has a unique feature absent in the fast and
slow skeletal muscle isoforms such that it possesses a 30-
aminoacidN-terminalextensionwhichcontainstwoProtein
Kinase A (PKA) phosphorylation sites (Ser 22 and 23) [10,
11]. Activation of PKA by β-adrenergic stimulation enhances
the rate of cross-bridge cycling and increases the rate of Ca2+
uptake by the sarcoplasmic reticulum [12–14]. Both of these
phenomenacontributetothelusitropiceﬀectassociatedwith
phosphorylation by PKA [15–17]. Occasionally, troponin
mutations may interfere with the processes involved with
thin ﬁlament phosphorylation and diminish the subsequent
Ca2+ desensitizing eﬀects.
The thin ﬁlament undergoes activation due to important
associations coordinated by cTnT. The N-terminal region
of cTnT anchors cTn to Tm and this interaction modulates
ATPase activation when Ca2+ concentrations achieve thresh-
old levels [18]. Cardiac TnT has two main interactions with
Tm. The ﬁrst is located in the N-terminus of cTnT and is
Ca2+ dependent [19]; and the second is located in the C-
terminal portion of cTnT which also interacts with cTnC
and cTnI [19, 20]. In addition to anchoring cTn to the
thin ﬁlament, cTnT has a critical role in the activation of
actomyosin ATPase activity [21]. When cTnT is combined
with cTnI-cTnC, the actomyosin ATPase is activated in a
Ca2+-dependent manner. Critical to this process is the region
of overlap that exists between TnT1 (residues 1–158) at the
head-to-tail junction of two adjacent Tm molecules [22, 23].
These interactions confer cooperativity to muscle activation
when Ca2+ reaches threshold levels [24]. Inhibition of
contraction is dependent on cTnI; however, in the absence
of TnI, both TnT and TnT1 are able to inhibit the actin
activated myosin subfragment-1 (S1) ATPase [22, 25].
3. RestrictiveCardiomyopathy inHumans
RCM is a rare cardiac disorder that manifests primarily as
an abnormality of diastolic ﬁlling which is also reported as a
reduced ventricular compliance or increased stiﬀness [26].
This results in a restriction of ventricular ﬁlling (reduced
diastolic volume) and an increase in end-diastolic pressure
while maintaining normal to near normal systolic function
[27]. Clinically, RCM presents in patients as dyspnea and
pulmonaryedema[28].Generally,bothatriabecomedilated,
which is likely due to the restriction of ventricular ﬁlling.
The heart may not be enlarged and the septal and ventricular
wall thickness dimensions are minimally aﬀected [29]. Over
time, the systolic function declines as the disease approaches
end stages and ultimately results in heart failure [30]. The
prognosis of RCM is poor, especially in pediatric cases
where heart transplantation is often the only preferred
treatment. SCD is prevalent in pediatric RCM with a two-
year mean survival rate for pediatric cases reaching ∼50%
after diagnosis [30–33]. SCD is also prevalent in pediatric
RCM cases that display electrocardiographic evidence of
ischemia [30].
Several studies conﬁrmed that restrictive cardiomyopa-
thy can be inherited in a familial manner (see Table 1). The
ﬁrst study in 1992 reported the familial inheritance of a
disease that resembled RCM and Hypertrophic Cardiomy-
opathy (HCM) [34]. In 2003, Mogensen and colleagues
ﬁrmly established that troponin I mutations were etiological
causes of RCM [35]. In one case, after evaluating a child
and his mother for RCM, examination of the extended
family revealed that 12 individuals had died suddenly, with
the surviving relatives presenting symptoms of heart disease
[35]. Linkage analysis identiﬁed a novel missense mutation
(D190H) in a conserved region of the cTnI gene (TNNI3)
that cosegregated in family members presenting symptoms
ofcardiacdisease.Thisstudyalsoincludedunrelatedpatients
with idiopathic RCM (IRCM) to assess if a genetic basis
could be determined. Genetic analysis of several pediatric
IRCM patients identiﬁed two diﬀerent de novo mutations
(R192H and K178E) in the TNNI3 gene. Additional patients
with adult onset IRCM were also evaluated and the genetic
analysis revealed three more mutations in the TNNI3 gene
(R145W, A171T, and L144Q) [35]. Notably, these mutations
cluster in speciﬁc regions of cTnI that participate in impor-
tant thin ﬁlament interactions.
Since 2005, numerous mutations linked to RCM have
been identiﬁed in the TNNI3 gene. A study utilizing a can-
didate gene approach identiﬁed the deletion of a nucleotide
in the TNNI3 gene that causes a frame shift in codon 168
from a 23-year-old patient diagnosed with RCM [36]. This
deletion resulted in a premature stop codon at position 176
which leads to the expression of a C-terminal truncated
mutant protein. During a six-year follow-up, the patient’s
heart had undergone progressive and concentric remodeling
of the left ventricle. A strong family history was also present
as the patient’s father had experienced SCD at age 29 and
two pregnant relatives experienced intrauterine fetal death
in their third trimester. At least two family members under
the age of 1 year had suddenly died. The authors established
that the frame shift mutation caused a 50% decrease in the
myocardium’s total cTnI content while the truncated cTnI
was undetectable. These results suggest that the frame shift
exerted its deleterious eﬀects through haploinsuﬃciency.
This might be due to cTnI degradation or the failure of
the mutant cTnI to associate with the thin ﬁlament. In
any event, the reduced cTnI content may lead to altered
interactions of cTn with the actin-tropomyosin complex that
resulted in severe diastolic dysfunction within this family
[36].
In 2008, Kaski et al. identiﬁed two other cTnI mutations
from two pediatric RCM patients [37]. The ﬁrst was a de
novo substitution (K178E) identiﬁed in a 7-year-old girl
who had biatrial enlargement, abnormal sinus rhythm and
ST-T waves. Histological evaluation of her cardiac tissue
revealed cardiomyocyte disarray. The second, identiﬁed in a
6-year-old girl, was a novel deletion of two nucleotides that
resulted in a frame shift at residue 177 and the occurrence
of a premature stop codon at residue 209. Her electrocar-
diogram also revealed abnormalities in sinus rhythm andJournal of Biomedicine and Biotechnology 3
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ST-T waves. Morphologically, her heart presented with bi-
atrial enlargement and dysplastic coronaries. Histological
evaluation showed cardiomyocyte disarray [37]. The authors
suggested that de novo mutations that arise in sarcomeric
proteins are generally associated with an earlier onset of the
disease and a more deleterious prognosis. These mutations
may result from germ line mosaicism [48]o rs o m a t i c
mutations that occur in heart progenitor cells [49].
Another HCM-associated TNNI3 mutation (R204H)
was recently identiﬁed in a young girl that developed bi-
atrial enlargement during her early teenage years which
developed into RCM. Her brother had died suddenly at age
18. Subsequently, she was under clinical observation and
developed RCM between the ages of 14–18. The patient had
frequent episodes of diastolic heart failure and underwent
a heart transplant at age 23. The histopathology performed
on her explanted heart showed an absence of hypertrophy,
even though myocyte disarray was evident which further
supported the RCM diagnosis [47].
Restrictive cardiomyopathy shares some similar clinical
features with HCM. For example, both diseases result in
the failure of the myocardium to relax fully during diastole.
Therefore, the diagnosis of patients with sarcomeric muta-
tions can be confounded when they present with IRCM and
HCM. The R192H cTnI mutation identiﬁed by Mogensen
in 2003 in an RCM patient [35] was also found in another
family in 2009 which presented with features of HCM [45].
The proband had a maximal left ventricular wall thickness
of 17mm, a restrictive physiology and a parent and sibling
diagnosed with RCM [45]. The R192H mutation is located
within the actin binding region of cTnI and is expected to
impair cardiac relaxation since it caused a decrease in the left
ventricular end diastolic dimension and enlarged the atria in
the patient [45]. Generally, RCM and HCM with restrictive
physiology caused by mutations in the TNNI3 gene have
worse clinical outcomes and disease progression.
Initially, familial RCM occurred primarily in the genes
encoding cTnI and cardiac desmin (DES)[ 26, 35, 36, 40,
47]. However, mutations in the α-cardiac actin (ACTC), β-
myosin heavy chain (β-MHC), and cTnT (TNNT2)g e n e s
have recently emerged as etiological causes of RCM [33, 37,
50]. In 2006, the ﬁrst mutation in the cTnT gene (TNNT2)
linked to RCM was identiﬁed in a patient, a deletion of Glu
at residue 96 [33]. This twelve-month-old girl was found
cyanotic and limp. Upon evaluation, her electrocardiogram
(ECG) revealed abnormal sinus rhythm, left axis deviation,
andnonspeciﬁcchangesintheST-Twave.Echocardiography
showed severe atrial dilation with no regurgitation of the
mitral and tricuspid valves. In addition, the patient had
mild-to-moderate left ventricular systolic dysfunction with
a reduced fractional shortening and mild right-ventricular
systolic dysfunction. While waiting for transplantation, she
experienced recurrent episodes of sinus brachycardia and
tachycardia associated with diﬀuse ischemic ECG changes
and pronounced hypertension [33].
Recently, another mutation (E136K) was identiﬁed in
the TNNT2 gene from a patient diagnosed with RCM [37].
Interestingly, the mutation was also identiﬁed in the father
and brother, who revealed nothing abnormal upon clinical
evaluation. Cardiac tissue from the explanted heart showed
that vacuolation was present but was lacking cardiomyocyte
disarray normally associated with cTnT-based cardiomy-
opathies. Since the two relatives were unaﬀected clinically,
the true etiology of the disease remains undetermined. It is
possible thatanotherundetected mutation contributesto the
phenotype seen in the RCM proband that was absent in the
relatives.
As the number of genes associated with RCM has
increased, it has become evident that mutations previously
determined to cause HCM can also cause RCM or HCM
with a restrictive phenotype. A study by Menon (2008)
identiﬁed a large family displaying cardiac disease inherited
in an autosomal dominant pattern. Characterization of the
RCM proband showed the existence of massive bi-atrial
enlargement and abnormal diastolic function [51]. However,
the proband had mild mid-septal hypertrophy without
left ventricular outﬂow obstruction. Interestingly, other
relatives presented with clinical features of RCM, HCM,
and/or dilated cardiomyopathy (DCM). It was suspected
that a single mutation was responsible for the variable
disease outcomes; therefore, a targeted linkage analysis was
performed for nine sarcomeric genes which determined that
the I79N mutation in the TNNT2 gene cosegregated with the
disease phenotype. Previously, this mutation was identiﬁed
in other individuals diagnosed with HCM [52, 53]. Studies
using transgenic mice containing the I79N TnT mutation
have shown that their cardiac function is consistent with a
restrictive physiology [54–56].
Other studies have also examined the prevalence and
clinical signiﬁcance of HCM with a restrictive phenotype.
Three previously characterized TNNI3 mutations (L144Q,
R145W, and D190G) were identiﬁed in patients manifesting
the restrictive phenotype. HCM is generally associated with
mild to moderate disability and normal life expectancies
as long as SCD is avoided; however, patients with the
“restrictive phenotype” have a very poor prognosis [39]. The
restrictive phenotype is characterized as an absence of or
minimal hypertrophy with restrictive ﬁlling, elevated rates
of atrial ﬁbrillation/ﬂutter, diastolic heart failure and stroke.
The overall survival rate of these patients is 56% ﬁve years
after diagnosis with the main cause of fatality being heart
failure [39]. Until recently, it was believed that HCM, DCM
and RCM were distinct and separate diseases. However, the
R145G and R145W mutations located at the same locus in
the cTnI gene can cause HCM or RCM, respectively. This
indicates that RCM is included in the spectrum of hereditary
cardiac contractile disorders [35, 57]. To date, the existence
of simultaneous multiple mutations, modiﬁer genes or the
inﬂuence of genetic background has not been fully explored.
These aspects will gain increasing interest as knowledge of
cardiomyopathies expands in the coming years.
4.Reconstituted andStructuralAssays
The functional eﬀects of cTnT and cTnI RCM mutations
have been explored in diﬀerent types of reconstituted
systems (see Table 1). The in vitro and in situ experimental
models involve skinned ﬁbers exchanged with RCM mutantJournal of Biomedicine and Biotechnology 5
proteins, myosin-actin-Tm-cTn reconstituted ATPase assays,
and spectroscopic measurements utilizing ﬂuorescence and
circular dichroism. Much of this data can be correlated
to the clinical observations seen in patients. Furthermore,
in addition to linkage analysis, these studies assist in
establishing de novo mutations as causative agents of the
disease.
4.1. Skinned Fiber Data. Skinned cardiac ﬁber experiments
provide a method of exploring myoﬁlament function with a
level of complexity that approaches the intact muscle. These
assays are considered one of the most relevant physiological
techniques available. Importantly, the sarcomeric proteins
at the M- and Z-band remain in the skinned ﬁber in
contrast to other reconstituted methods. These experiments
measure the Ca2+ buﬀering capacities of the myoﬁlament
while measuring the development of tension or maximal
force [58, 59] .S e v e r a lg r o u p sh a v ea l s or e p o r t e dd i ﬀerences
in the level of basal force (at low Ca2+ concentrations) after
the incorporation of mutant cTnT or cTnI [38, 41].
Our group ﬁrst investigated the functional eﬀects of
cTnI mutations linked to RCM [41]. All ﬁve RCM mutants
that were investigated (L144Q, R145W, A171T, K178E, and
R192H) increased the Ca2+ sensitivity of force development
in skinned ﬁbers. The maximal tension was diminished for
all mutants, except R192H. The L144Q, R145W, and K178E
mutantsshowedasigniﬁcantincreaseinthebasalforcelevels
compared to WT [41]. Other studies using these mutants
also produced a large leftward shift in the Ca2+ sensitivity
of force development in exchanged cardiac skinned ﬁbers
[40]. The maximal force was reduced in the presence of
the L144Q, R145W, A171T, and R192H mutants; however
D190G had no eﬀect on the maximal force when compared
to the WT [40]. Using adenoviral gene transfer techniques,
Davis et al. introduced RCM mutations into cardiomyocytes
andstudiedtheirfunctionalconsequencesatthecellularlevel
[42]. In contrast to the previous study [41], skinned rat
cardiomyocytes containing the rat cTnI mutations, L145Q
and R146W (corresponding to L144Q and R145W), did not
show changes in the Ca2+ sensitivity of force development
[42]. It is possible that the cTnI mutants located in the
inhibitory peptide were poorly incorporated into the thin
ﬁlament which could mask the eﬀects of the mutations
on the Ca2+ sensitivity of contraction. However, the rat
cTnI mutations, A172T, K179E and D191G (corresponding
to human A171T, K178E, and D190G) increased the Ca2+
sensitivity of force development [42]. Moreover, the trans-
fected cardiomyocytes bearing the mutant cTnIs could be
desensitized to Ca2+ upon PKA treatment [42], however,
these mutations did not inﬂuence the ability of cTnI to
respond to adrenergic stimulation. In a separate study, Davis
et al. investigated the functional eﬀects of the cTnI R193H
mutant incorporated into the thin ﬁlament which caused
signiﬁcantCa2+ sensitizationofthemyoﬁlamentsandslowed
the Ca2+ transient decay rate [46].
Previously,westudiedthefunctionalconsequencesofthe
ﬁrst cTnT mutation related to RCM where glutamic acid
was deleted at position 96 (cTnT-E96) [38]. The skinned
ﬁber measurements showed signiﬁcant Ca2+ sensitization of
the myoﬁlaments and the mutant cTn complex increased
the basal force after troponin exchange. The mutation did
not aﬀect the maximal force recovery at saturating Ca2+
concentrations. In addition, the same mutation was also
studied as the corresponding residue of the fetal isoform of
cTnT (cTnT1). Interestingly, in the fetal environment, i.e.,
the cTn complex containing the cTnT isoform 1 (cTnT-
ΔE106) and slow skeletal TnI, the mutation caused a less
pronounced eﬀect than when in the adult environment
[38]. This suggests that fetal cTn isoforms have a protective
role and may explain why the disease occurs early after
birth. The mutation signiﬁcantly reduced the cooperativity
(i.e., nHill)o fC a 2+ binding to the regulatory units. This
information canbecorrelatedwiththepreviousﬁndings and
related to the time of onset and the severity of the disease
[60].
4.2. Myosin-Actin-Tm-Tn ATPase Assays. The measurement
of myoﬁlament ATPase activity is very important since these
experiments indicate the ability of the troponin complex
to initiate activation and inhibition of the myosin-actin
ATPase activity. The Ca2+ concentration can be adjusted
to activate or inhibit the ATPase activity. In other words,
this experiment evaluates the inﬂuence of Tn in modulating
cross-bridge kinetics. Additionally, it is possible to measure
the rate of ATP hydrolysis as a function of the free Ca2+
concentration.
In an elegant set of experiments, Gomes et al. showed
the dependence of diﬀerent ratios of WT and mutant cTnI
related to RCM on the ability to inhibit the ATPase activity.
For example, cTnI R145W in a 50%:50% mixture with
WT was able to fully inhibit the ATPase; however L144Q
in a 50%:50% ratio with WT had the greatest inability to
inhibit ATPase activity and had a dominant regulatory eﬀect
over the WT. Regarding the acto-myosin ATPase activation,
cTn containing the L144Q mutation partially lost its ability
to activate [41]. Kobayashi and Solaro also investigated the
functional consequences of the R145W, D190H, and R192H
RCM mutations in cTnI. All of the RCM mutants markedly
increased the Ca2+ sensitivity of ATPase activity. In addition,
theR145Wmutantwhichislocatedintheinhibitory portion
ofcTnIshowedanincreaseinthebasalATPaseactivityatlow
Ca2+ concentrations [44]. These experimental results suggest
that RCM mutations in the inhibitory peptide have a more
drastic eﬀect than mutations located in the cTnI C-terminal
domain. In the absence of Ca2+, the inhibitory region is very
important for maintaining proper thin ﬁlament function in
the oﬀ state.
Thin ﬁlaments reconstituted with the ﬁrst described
cTnT mutant (E96) were used to measure actomyosin
ATPase activity. In the presence of this mutant, the acto-
myosin ATPase activity was poorly inhibited at low Ca2+
levels. However, it appears that introducing the mutation
into the fetal cTnT isoform in the presence of the fetal slow
skeletal TnI diminished these deleterious eﬀects [38].
These functional studies conﬁrm that the RCM phenotype
can be directly correlated with clinical data obtained from
patients. For example, the increased Ca2+ sensitivity, impaired
inhibition of ATPase activity by the Tn complex containing6 Journal of Biomedicine and Biotechnology
RCM mutants, and increased basal force can be directly
correlated with diastolic dysfunction.
4.3. Spectroscopy Measurements. Steady-state ﬂuorescence
measurements were used to show that the R145W, D190H
and R192H cTnI RCM mutants only increased the apparent
Ca2+ binding aﬃnity of cTnC in the presence of the other
thinﬁlamentcomponents[44].StructuralstudieswithNMR
using the 13C/15N-labeled cTnI129–210 peptide containing the
K178E RCM mutation revealed local structural changes in
the region immediately adjacent to the mutated residue. The
cTnI K178E mutant was also evaluated by circular dichroism
and no changes were observed in the cTnI K178E structure
compared to WT [40]. Together, this data suggests that local
yet minor changes in the structure of the isolated mutants
may disrupt crucial interactions with other thin ﬁlament
proteins. In general, the alteration of a few key residues in
s i t e so fi n t e r a c t i o n sm a yb es u ﬃcient to alter cTn function.
5. Transgenic Models
A speciﬁc functional phenotype is emerging for RCM that
includes large increases in the Ca2+ sensitivity of tension,
impaired ability to inhibit the myosin ATPase activity and
increased basal force in skinned ﬁbers. All of these factors
when manifested in vivo can contribute to severe diastolic
dysfunction and may account for the RCM disease [61]. One
of the advantages of using animal models is that the mutant
protein is naturally incorporated into the thin ﬁlament.
Therefore, characterizing the eﬀects of RCM mutations in
transgenic or knock-in animals is imperative in determining
if cardiac function is aﬀected. Unlike HCM and DCM,
the diagnosis of RCM is not based on the morphological
appearance of the heart but primarily on the properties of
the working heart. Abnormal diastolic ﬁlling is the primary
defect that leads to increased myocardial stiﬀness and higher
ventricular pressures [27–29, 61].
Two transgenic mouse models for cTnI RCM mutations
have been reported which investigated the physiological
eﬀects of the R192H and R145W mutations. Du et al.
designed a transgenic mouse carrying the R193H mutation
(which corresponds to human R192H) and evaluated its
eﬀects on gross cardiac morphology. The transgenic R193H
mice demonstrated RCM characteristics, i.e., atrial dila-
tion and decreased left ventricular end-diastolic dimension
without signiﬁcant changes in systolic function. Also, they
observed a signiﬁcant change in the ejection fraction in
middle aged (11 months old) mice. Histological evaluation
indicated that the cardiac tissue was structurally normal
[62].Functionally,themostsigniﬁcantchangesthatoccurred
were impaired relaxation manifested by prolonged IRT
(isovolumic relaxation time) and DT (deceleration time).
The restrictive physiology was evident by the reduced E
peak velocity and reversed E/A on doppler tissue imaging
[63]. These observations directly correlated with the clinical
phenotype used to establish RCM in a patient.
In another study, Du et al. evaluated the progression of
RCM in a cTnI R193H transgenic mouse over a period of 12
months. During this time, cardiac function was assessed to
monitor the development of diastolic dysfunction. Initially,
the mutation caused abnormal relaxation which gradually
manifested as diastolic dysfunction as age progressed. High-
resolution echocardiography was used to characterize the
mutation’s eﬀects on diastolic function by a reversed E to
A ratio, increased DT and prolonged IRT. Some of the
cTnI R193H middle-aged mice (1 year) had a signiﬁcant
reduction in cardiac output and a few died from congestive
heart failure. Morphologically, the mutant mouse hearts
had dilated atria and ventricular restriction similar to those
of RCM patients carrying the cTnI R193H mutation. The
mutation aﬀected mouse cardiac function in the same
manner as seen in the patients by recapitulating the diastolic
dysfunction and diastolic heart failure. Altogether, this data
suggests that the C-terminus of cTnI plays an important role
in maintaining the diastolic parameters of the heart [63].
The cTnI R145W RCM mouse model was investigated
to determine how a diﬀerent substitution at the same locus
which causes HCM (R145G) can lead to two diﬀerent
diseases [57]. In transgenic R145W cardiac myoﬁbrils, an
increase in the Ca2+ sensitivity of force and ATPase was
observed. Interestingly, the intracellular Ca2+ and force
transients measured in intact ﬁbers were delayed which
may contribute to the diastolic dysfunction. One possible
explanation for the distinct phenotypic diﬀerences between
RCM and HCM is the presence of an increase in the maximal
force as observed only in the R145W mice. The contractility
of the ventricular muscle containing the R145W mutant is
increased 53% during systole, thus compensating for the
diastolic dysfunction. In contrast, the R145G HCM mice
showed a decrease in the maximal force which may explain
why the development of cardiac hypertrophy occurs [43].
6. Isoform Switch, DiseaseOnset, and Lethality
During fetal heart development, the expression and presence
of diﬀerent isoforms of cTnI and cTnT varies. These changes
in isoform expression may underlie the early onset and
aggressive course of pediatric cardiomyopathies. The slow
skeletal TnI isoform is a product of a distinct gene and
is expressed and incorporated in the heart during fetal
and neonatal development. The eﬀects of mutations in the
cardiac isoform of TnI appear later, as regulated by the
activation of cTnI gene expression. It was determined in
the rat that cTnI is expressed by the fourth day after birth
and isoform switching continues up to the fourteenth day
[64, 65]. Mutations in the cardiac TnI gene that change cTn
function would consequently alter the Ca2+ homeostasis of
the cell and manifest their deleterious eﬀects shortly after
birth. Cardiac TnT also undergoes an isoform switch. The
fetalheartexpressesadiﬀerentisoformbyalternativesplicing
of the TNNT2 gene. The fetal isoform of cTnT (cTnT1)
containsbothexons4and5,whiletheadultisoform(cTnT3)
contains only exon 4 [66–68]. When the corresponding
RCM mutation (E96 adult isoform cTnT3) was introduced
into cTnT1 (i.e., E106) in the presence of slow skeletal
TnI, the functional eﬀects were less dramatic [38]. This
observation suggests that the combination of fetal cTnT and
ssTnI isoforms can rescue the eﬀects of an RCM mutation inJournal of Biomedicine and Biotechnology 7
thecTnTgene.Incontrast,throughoutcardiacdevelopment,
cTnC is continually expressed; therefore, it is expected that
RCM causing mutations in cTnC may lead to late term or
spontaneous abortion. This may explain why mutations in
cTnC linked to RCM have not been identiﬁed yet.
7. StructuralConsideration and Perspectives
The two reported cTnT RCM mutations are located in a hot
spot region of the TnT N-terminal domain which interfaces
with Tm. We speculate that the mutations in cTnT may
disrupt the communication between TnT-Tm and thus aﬀect
the actomyosin interaction and cooperative activation of the
thin ﬁlament. Therefore, future investigations using cTnT
RCM mutants may help to dissect the modulatory role and
function of the cTnT N-terminal domain.
The RCM mutations found in TnI are located within the
inhibitory peptide or within the C-terminal domain. The C-
terminaldomainofcTnIbindstoactinandhelpstomaintain
the thin ﬁlament in a blocked state. These cTnI mutations
maybedestabilizing,i.e.,decreasingtheinteractionsbetween
thecTnIC-terminaldomainandactinintheabsenceofCa2+,
consequently relieving cTnI inhibition. The small region
termed the inhibitory peptide is necessary for the regulatory
role of cTnI on muscle contraction. It is also possible that
mutations located within the cTnI C-terminal domain may
alter the structure and function of the inhibitory peptide.
The discovery of new mutations in RCM patients is
crucial for dissecting how they alter function and may lead
to a better understanding of the disease. The functional and
clinical data should be weighed equally in order to better
link mutations as causes of cardiomyopathies. In addition,
functional studies may help to further deﬁne the RCM and
HCM phenotypes which share similar features, such as,
an increase in the Ca2+ sensitivity of force development.
Exploration of RCM causing mutations provides an excellent
framework on which new therapeutic strategies can be
developed to target the eﬀects of this disease.
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